Lavie Bio intends to commence
Yalos® sales for soybean in 2025 US spring
season
REHOVOT, Israel, Nov. 12,
2024 /PRNewswire/ -- Lavie Bio Ltd., a leading
ag-biologicals company and a subsidiary of Evogene Ltd. (Nasdaq:
EVGN) (TASE: EVGN), today announced the commercial expansion
of Yalos® seed-treatment to soybean, following successful field
trials performed in 2024 in the US. Yalos®, Lavie Bio's first commercial bio-inoculant
product available in the US and Canada, demonstrated yield increase by more
than 5% on average, in soybean.
Yalos® is comprised of two novel microbes that together improve
early vigor, biomass, root and shoot development, and nutrient
availability. It aims to improve emergence and establishment and
increase farm productivity through advanced biological
technologies. Currently, Yalos® is sold in North America as a seed-treatment for spring
and winter wheat, durum and barley, distributed in Canada by Winfield United and in the US
directly by Lavie Bio. As of spring
2025, Lavie Bio intends
Yalos® to be commercially available for soybean as
well.
Soybean represents an additional 86 million acres in market
potential for Yalos® in the US alone[1]. This expansion
more than doubles the potential market for Yalos® compared to
markets in which Lavie Bio already
operates.
Throughout the soybean field trial series, Yalos® has
repeatedly demonstrated increased crop vigor, improved
establishment and plant health, consistently supporting its
effective performance. The trials took place in US soybean growing
regions, representing different varieties and soil conditions,
showing an average increase in soybean yield of more than 5%, a
significant improvement in this crop.
"The addition of soybean to crops effectively treated by Yalos®
is a significant achievement," stated Amit Noam, Lavie
Bio's CEO. "We are very pleased with the results and are
excited to bring innovation to soybean growers across North America. With Yalos'® winter wheat
positive results, on which we announced earlier this year, and with
the current promising results in soybean, Lavie Bio is looking forward to a global
expansion of Yalos® into Brazil
and European markets in the coming years".
About Lavie Bio Ltd.
Lavie Bio, a subsidiary of
Evogene Ltd., aims to improve food quality, sustainability, and
agriculture productivity through the introduction of
microbiome-based ag-biological products. Lavie Bio utilizes a proprietary computational
predictive platform, the BDD platform, powered by Evogene's
proprietary MicroBoost AI tech-engine, harnessing the power of big
data, artificial intelligence, and advanced informatics, for the
discovery, optimization and development of bio-stimulant and
bio-pesticide products.
For more information, please visit www.lavie-bio.com.
About Evogene Ltd.
Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology
company aiming to revolutionize the development of life-science
based products by utilizing cutting edge technologies to increase
the probability of success while reducing development time and
cost. Evogene established three unique tech-engines - MicroBoost
AI, ChemPass AI and GeneRator AI – leveraging Big Data and
Artificial Intelligence and incorporating deep multidisciplinary
understanding in life sciences. Each tech-engine is focused on the
discovery and development of products based on one of the following
core components: microbes (MicroBoost AI), small molecules
(ChemPass AI), and genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through
subsidiaries and strategic partnerships. Evogene's subsidiaries
currently utilize the tech-engines to develop human
microbiome-based therapeutics by Biomica, ag-biologicals by
Lavie Bio, ag-chemicals by AgPlenus,
medical cannabis products by Canonic and castor varieties, for the
biofuel and other industries, by Casterra.
For more information, please
visit: www.evogene.com.
Forward Looking Statements
This press release contains "forward-looking statements"
relating to future events. These statements may be identified by
words such as "may", "could", "expects", "hopes" "intends",
"anticipates", "plans", "believes", "scheduled", "estimates",
"demonstrates" or words of similar meaning. For example, Evogene
and its subsidiaries are using forward-looking statements in this
press release when they discuss the ability of Yalos® to
achieve yield increase in soybean and to reduce crop abandonment
rates and increase farm productivity. Such statements are based on
current expectations, estimates, projections and assumptions,
describe opinions about future events, involve certain risks and
uncertainties which are difficult to predict and are not guarantees
of future performance. Therefore, actual future results,
performance or achievements of Evogene and its subsidiaries may
differ materially from what is expressed or implied by such
forward-looking statements due to a variety of factors, many of
which are beyond the control of Evogene and its subsidiaries,
including, without limitation, the current war between Israel and Hamas and any worsening of the
situation in Israel such as
further mobilizations or escalation in the northern border of
Israel and those risk factors
contained in Evogene's reports filed with the applicable securities
authority. In addition, Evogene and its subsidiaries rely, and
expect to continue to rely, on third parties to conduct certain
activities, such as their field-trials and pre-clinical studies,
and if these third parties do not successfully carry out their
contractual duties, comply with regulatory requirements or meet
expected deadlines, Evogene and its subsidiaries may experience
significant delays in the conduct of their activities. Evogene and
its subsidiaries disclaim any obligation or commitment to update
these forward-looking statements to reflect future events or
developments or changes in expectations, estimates, projections and
assumptions.
[1]
https://www.nass.usda.gov/Publications/Todays_Reports/reports/acrg0624.pdf
Contact:
ir@evogene.com
Tel: +972-8-9311901
Logo - https://mma.prnewswire.com/media/945133/lavie_bio.jpg
Photo -
https://mma.prnewswire.com/media/2554171/Yalos_Soybean.jpg
Logo - https://mma.prnewswire.com/media/1947468/Evogene.jpg
View original
content:https://www.prnewswire.com/news-releases/lavie-bio-announces-commercial-expansion-of-yalos-as-seed-treatment-for-soybean-following-successful-field-trials-302302348.html
SOURCE Lavie Bio
